Rapid Micro Biosystems to Present at TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Rapid Micro Biosystems (Nasdaq: RPID) will present at the TD Cowen 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026 at 10:30 a.m. Eastern Time. The presentation will be webcast live and archived for later replay.
According to the company, the live webcast will be available on its investor relations website and accessible for on-demand viewing after the event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
RPID is up 6.3%, while peers show mixed moves: OWLT +3.33%, PROF +4.08%, LNSR +1.76%, but RCEL -3.1% and SERA -4.38%. No peers appeared in the momentum scanner, pointing to a stock-specific move rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Earnings date notice | Neutral | +6.3% | Scheduled Q4 and full-year 2025 earnings release and webcast details. |
| Feb 12 | Inducement grants | Neutral | +2.8% | Equity inducement awards of RSUs and options to new employees. |
| Jan 13 | Prelim revenue update | Positive | +21.1% | Record preliminary Q4 and 2025 revenue with system placements growth. |
| Jan 07 | Conference presentation | Neutral | -1.2% | Planned presentation at J.P. Morgan Healthcare Conference with webcast. |
| Nov 18 | Growth capital financing | Positive | +5.3% | $45M growth capital commitment to support platform scaling and expansion. |
Recent company updates, especially revenue and financing news, have generally seen positive price alignment, while conference appearances have had modest impact.
Over the past few months, Rapid Micro Biosystems has reported several notable developments. On Jan 13, 2026, it announced record preliminary unaudited Q4 and full‑year 2025 revenue, which coincided with a 21.05% gain. A $45 million growth capital commitment disclosed on Nov 18, 2025 saw shares rise 5.31%. By contrast, a presentation at the J.P. Morgan Healthcare Conference on Jan 7, 2026 was followed by a small -1.18% move. The current TD Cowen conference notice fits this pattern of generally neutral conference headlines alongside stronger reactions to financial and growth updates.
Market Pulse Summary
This announcement outlines Rapid Micro Biosystems’ participation at the TD Cowen health care conference on March 3 at 10:30 a.m. ET, with a webcast and replay available to investors. In recent months, the company highlighted record preliminary 2025 revenue and secured a $45 million growth capital commitment, both followed by positive share reactions. Investors may watch for any new disclosures or guidance commentary around the event, alongside ongoing insider equity activity and upcoming full-year results.
AI-generated analysis. Not financial advice.
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the TD Cowen 46th Annual Health Care Conference in Boston, MA.
The Company is scheduled to present on Tuesday, March 3 at 10:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
FAQ
When will Rapid Micro Biosystems (RPID) present at the TD Cowen 46th Annual Health Care Conference?
How can investors watch Rapid Micro Biosystems' (RPID) TD Cowen presentation live or later?
Where will Rapid Micro Biosystems (RPID) host the archived replay of the TD Cowen presentation?
What topics will Rapid Micro Biosystems (RPID) likely cover in its TD Cowen conference presentation?
Will Rapid Micro Biosystems (RPID) provide a webcast link for the TD Cowen presentation?
